Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

Millions of people with hypothyroidism depend on levothyroxine every day to replace the thyroid hormone their body cannot produce.

Now, the U.S. Food and Drug Administration (FDA) has announced a nationwide recall of certain batches of levothyroxine sodium tablets after they were found to be subpotent, meaning they contain less active medication than stated on the label.

Experts caution that ingesting a lower-than-prescribed dose could allow hypothyroidism symptoms to return, particularly in vulnerable groups like pregnant women, infants, and people with thyroid cancer.

Why Did FDA Recall Levothyroxine?

The FDA has issued a Class II recall for specific lots of levothyroxine sodium tablets distributed by Major Pharmaceuticals. Testing found that the recalled tablets were below the approved potency specification, meaning they may not deliver the intended amount of thyroid hormone.

The recall affects multiple strengths packaged in 100-tablet cartons and 10-count blister packs. Dosages involved include 25 mcg, 50 mcg, 75 mcg, 88 mcg, 112 mcg, 125 mcg and 150 mcg.

The FDA has categorized the action as a Class II recall. According to the agency, a Class II recall means: "Use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."

This means the recall is important but does not come under FDA's highest-risk category.

Also read: Is Your Allergy Medicine Safe? FDA Recalls Antihistamine Tablets Over Life-Threatening Contamination Concerns

Why A Subpotent Thyroid Medicine A Concern?

Even relatively small differences in levothyroxine dose can affect how well the medicine works. If they contain less hormone than needed, patients may receive insufficient thyroid replacement. Possible consequences include:

• Fatigue
• Weight gain
• Feeling unusually cold
• Constipation
• Depression or low mood
• Brain fog
• Dry skin
• Slower heart rate

In some higher-risk individuals, inadequate thyroid hormone replacement could have more severe consequences, including worsening hypothyroidism or interference with thyroid cancer treatment.

Also read: CDC's 'Vaccines Do Not Cause Autism' Webpage Sparks Debate; Republican Senator Seeks Clarity

What Does This Recall Mean For Patients?

Because thyroid hormone influences nearly every organ system, taking the correct dose consistently is essential.

Also read: Montelukast Mental Health Warning Still Largely Overlooked By Psychiatrists

Do not stop taking levothyroxine on your own. Stopping thyroid medication suddenly can lead to worsening hypothyroidism and other complications. Instead, patients should:

• Check whether their medication's lot number matches the recalled batches.
• Contact your pharmacist or physician.
• Obtain a replacement if their medication is affected.
• Continue treatment unless instructed otherwise by a healthcare professional.

Other Recently Recalled Medications

The FDA also announced recently that it is recalling four lots of Cetirizine Hydrochloride Tablets USP 5 mg made by India-based company Unique Pharmaceutical Laboratories due to potential cross-contamination with ranitidine, a medication used to treat heartburn and stomach ulcers.

Although Unique Pharmaceutical Laboratories said it has not received any reports of adverse reactions related to the recalled tablets, the contamination could pose a serious risk for people who are allergic or hypersensitive to ranitidine.

The latest FDA recall serves as a reminder that quality control remains critical for medications taken every day. For anyone taking levothyroxine, experts recommend checking medication packaging against the FDA recall notice and speaking with a healthcare provider or pharmacist if there is any uncertainty.

Florida is once again reporting an increase in Hansen's disease (leprosy) cases, renewing attention to a disease that got eradicated decades ago.

While the infection remains rare in the United States, health officials say Florida continues to report one of the country's highest numbers of locally acquired cases, with recent infections concentrated in several Central Florida counties.

According to the Florida Department of Health, 17 cases of leprosy had been reported statewide through mid-July 2026, with multiple cases identified in Brevard, Lake, Orange, Seminole, Sumter, and Volusia counties.

Local health experts say the disease is uncommon but not unexpected in Florida, where environmental and wildlife factors contribute to its persistence.

Why Does Leprosy Still Exist In Florida?

Also read: WHO Declares Australia Free Of Trachoma: All About The Irreversible Blindness

Unlike many parts of the world where leprosy is associated human-to-human transmission, Florida has a unique risk factor: wild nine-banded armadillos.

Research has shown that armadillos are natural reservoirs of Mycobacterium leprae, the bacterium that causes leprosy.

Humans may become infected after frequent contact with infected armadillos or contaminated soil where the bacteria may persist. Experts emphasize that not every armadillo carries the bacteria.

Scientists also believe Florida has become endemic for leprosy, meaning the disease is now established locally rather than being introduced through international travel.

Increasing numbers of patients have reported no history of foreign travel or known contact with someone diagnosed with leprosy, suggesting local transmission is still prevalent.

All About Leprosy

Also read: Chile Becomes The First Country In Americas To Eliminate Leprosy, Says WHO

Leprosy, also known as Hansen's disease, is a chronic bacterial infection caused primarily by Mycobacterium leprae. The disease mainly affects:

• Skin
• Peripheral nerves
• Eyes
• Upper respiratory tract lining

If diagnosed early, it is completely curable. Delayed treatment, however, can result in permanent nerve damage, muscle weakness, and disability.

How Does It Spread?

Contrary to longstanding myths, leprosy is not highly contagious. Health experts say the infection usually spreads through prolonged, close contact with untreated individuals, likely via respiratory droplets.

Casual interactions like shaking hands, hugging, sharing meals, or sitting next to someone do not typically spread the disease.

The illness also has an unusually long incubation period, often taking 2 to 20 years before symptoms appear, making it difficult to identify exactly where and when an infection occurred. Early symptoms may include:

• Pale or reddish skin patches with reduced sensation
• Numbness in the hands or feet
• Tingling or nerve pain
• Muscle weakness
• Thickened peripheral nerves

Because symptoms develop gradually, many patients are diagnosed only after nerve damage has already begun.

Experts advise avoiding unnecessary handling of wild armadillos and seeking medical evaluation for persistent numb skin lesions, especially after possible exposure

Although leprosy is curable, its persistence in Florida highlights how infectious diseases can survive in animal reservoirs even after becoming rare in humans.

Public health experts say improving awareness among both doctors and the public is essential for early diagnosis, timely treatment, and preventing permanent disability.

The U.S. Centers for Disease Control and Prevention's (CDC) revised webpage on autism and vaccines has reignited debate over how health agencies should communicate scientific evidence.

Republican Senator Bill Cassidy slammed the agency's messaging while continuing to defend the overwhelming scientific evidence that vaccines do not cause autism.

CDC Makes Changes To Its Autism And Vaccine Webpage

The controversy was sparked on changes made to the CDC's autism webpage, which now states that the claim "vaccines do not cause autism" is "not an evidence-based claim" as studies have not ruled out every possible link between infant vaccines and autism.

The page also says the U.S. Department of Health and Human Services (HHS) is continuing to investigate the causes of autism.

The revised language represents a shift from the CDC's longstanding public messaging, which for years stated that extensive scientific research had found no causal relationship between vaccines and autism.

The changes have drawn criticism from scientists, physicians, and lawmakers who fear they could weaken public confidence in routine childhood immunization.

Also read: US FDA Identifies New Cyclospora Outbreak As Michigan Cases Top 7,000: Why Is The Source So Hard To Trace?

Republican Senator Bill Cassidy Reacts

Sen. Bill Cassidy, a Louisiana Republican, physician, and chairman of the Senate Health, Education, Labor and Pensions Committee, recently said discussions with CDC Director nominee Dr. Erica Schwartz and HHS officials led to what he described as a "good faith" revision of the webpage.

"As a sign of good faith, HHS modified the CDC's autism and vaccines webpage. There is more to do to repair the damage that has been done to the U.S. public health response, but this is a start," Cassidy said.

Cassidy had previously questioned whether future CDC leadership would protect scientific integrity and resist political pressure on vaccine policy during Schwartz's Senate confirmation hearing.

While Cassidy ultimately announced his support for Schwartz's nomination, he has continued to stress that the agency should responsibly communicate established scientific evidence regarding vaccines.

Also read: Legionnaires' Disease Claims 5th Life In New York City: Health Officials

Scientific Consensus Remains Intact

Despite the debate surrounding the CDC webpage, the broader scientific consensus has not changed.

Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.

Major medical organizations continue to support vaccination as one of the safest and most effective public health interventions.

Health experts have also warned that ambiguous or conflicting public health messaging could further affect vaccine confidence at a time when the United States is experiencing its highest number of measles cases in more than three decades, largely driven by declining childhood vaccination rates.

The controversy highlights the growing tension between political oversight and scientific communication within U.S. public health agencies.

For public health experts, the concern extends beyond a single webpage. They argue that how government agencies present scientific evidence can directly influence vaccine confidence, healthcare decisions, and efforts to prevent outbreaks of vaccine-preventable diseases.